Open AccessLong lasting octreotide LAR therapy in non functioning pancreatic neuroendocrine carcinoma
Author(s) -
Ivan Lolli,
Antonio Logroscino,
Simona Vallarelli,
Maria A. Monteduro,
Antonella Gentile,
G Troccoli
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i1s.1067
Subject(s) - medicine , octreotide , endocrine system , somatostatin receptor , somatostatin , gastroenterology , disease , hormone , oncology
Non functioning endocrine pancreatic tumors (NF-PETs) have absent or low hormone secretion without symptoms and constitue ~60% of PETs. At diagnosis more than 50% of patients have liver metastases and almost 40% are not candidates for radical surgery because of either locally advanced disease or unresectable metastases. We described the case of a 47-year-old woman with a pancreatic carcinoma with secondarism in the liver not suitable for radical surgery. Histological test of liver metastases showed positivity for endocrine well-differentiated non functioning carcinoma expressing receptors for somatostatin with very low proliferation index (Ki67 < 2%). After this diagnosis she started a specific treatment with octreotide analogues which achieved durable stabilization of the disease.